SymBiosis and SIG-backed microbiome therapeutics developer Finch priced an upsized offering at the top of its range.
Finch Therapeutics, a US-based microbiome therapeutics developer backed by quantitative trading firm Susquehanna International Group (SIG) and medical services provider SymBiosis, floated on Friday in a $128m initial public offering.
The company issued 7.5 million shares on the Nasdaq Global Select Market, upsized from 6.3 million. They were priced at the top of the IPO’s $15 to $17 range and opened at $20.45 on their first day of trading, closing at $21.32.
Founded in 2014, Finch is developing drugs to…
